ADAM17 and hilar cholangiocarcinoma: Strong expression of ADAM17 was found associated to poor prognosis or aggressive disease progression in gastric cancer [40,41,42,43], hilar cholangiocarcinoma [44], cervical [45], esophageal [46], non-small-cell lung cancers [47] and in high-grade breast tumors [48].